Brigatinib‐induced psoriasiform dermatitis successfully treated with deucravacitinib

Wei-Lun Liu declared no conflict of interest. Yung-Tsu Cho has served as sub investigators for AbbVie, Amgen, Boehringer Ingelheim, Dermira, Janssen, Eli Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi and has received speaker fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Novartis, Pfizer, Roche, Sanofi, and Viatris.